Valuation check: LEGN's profit margin is -7.22%, below the Healthcare sector average of 13.89%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Legend Biotech (LEGN) currently reports a profit margin of -7.22% as of June 2026. That compares with -40.84% in the prior-year period — up 82.3% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Legend Biotech's profit margin history and peer comparisons.
Legend Biotech's profit margin increased from -40.84% to -7.22% — a 82.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Legend Biotech's profit margin of -7.22% is lower than the Healthcare sector average of 13.89%. That is roughly 152.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Legend Biotech's current -7.22% should be judged against Healthcare norms (sector average: 13.89%) and against LEGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -7.22%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Legend Biotech, and consider following LEGN for alerts when major investors trade the stock.